Posted on

Breakthrough Cooperation of Legend Capital’s Cross-border Portfolio Companies: Innovent and Etana Jointly Announce the Approval of Bevagen by the BPOM

HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - On June 14, two of Legend Capital's portfolio companies, Innovent Biologics, Inc. ("Innovent") and PT Etana Biotechnologies Indonesia ("Etana"), jointly announced that the Indonesian Food and Drugs Authority (BPOM) had approved Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for five indications including metastatic colorectal cancer (mCRC), metastatic triple-negative breast cancer (mTNBC), advanced non-small cell lung cancer(NSCLC), ovarian cancer (OC), and cervical cancer(CC). Under the approval of the BPOM, Bevagen will potentially be the first Chinese antibody drug to be marketed and locally produced in Southeast Asia.Dr. Michael Yu, Founder, Chairman and CEO of Innovent, said, "We are pleased that under the strategic collaboration with Etana, the approval of Bevagen in Indonesia marked a meaningful step toward bringing Innovent's innovative portfolio into the global market, benefitting patients globally. Pairing Etana's commercial expertise in the local Indonesian market with Bevagen's clinical profile, high-quality production and relative affordability, we are confident that Bevagen will launch to the market quickly and benefit many cancer patients."Nathan Tirtana, President Director of Etana, said, "Etana appreciates the support of BPOM for approving Bevagen for cancer patients in Indonesia. With this product, we believe we can provide better access to high-quality and affordable biosimilar drug to meet the need of cancer patients in Indonesia. Our next step is to implement the technology transfer and local Bevagen production in Indonesia via collaboration with Innovent."Legend Capital has been looking for investment and partnership opportunities in the Southeast Asian market since 2019 and ultimately invested in Etana in 2020. By leveraging the advantages of the portfolio ecosystem, Legend Capital has played an active role in promoting the strategic cooperation between Innovent and Etana.Mr. Frank Hong, Managing Director of Legend Capital, said, "Congratulations to Innovent and Etana for the approval of the first biosimilar in Indonesia. This milestone achievement demonstrates the feasibility of expanding Chinese innovative drugs market access into the emerging markets. The emerging markets along the Belt and Road have significant demand for pharmaceutical products and unmet clinical needs, Chinese innovative therapeutics are particularly well suited to the needs of patients in developing countries given their quality and affordable prices. Legend Capital will continue to explore investment opportunities in the emerging markets and actively pioneer the path for Chinese high-end biologics' overseas expansion, facilitating the globalization of Chinese pharmaceutical companies."Mr. Fei Qi, Executive Director of Legend Capital, said, "The cross-border investment and industrial collaboration in the Southeast Asian market possess unique challenges: from policy regulation, folk culture to healthcare system complexity. Etana has set up a competitive barrier of 'Access + Manufacturing + Commercialization' in Southeast Asia, and Legend Capital complemented Etana's key 'Business Development' ability by leveraging its healthcare portfolio ecosystem. Legend Capital has provided a series of value-add services in terms of company strategy, business cooperation and subsequent financing to Etana since its investment. Etana has approached and discussed collaboration initiatives with more than 10 Chinese biopharmaceutical companies and plans to introduce more therapeutics that Indonesia currently lacks, such as cancer monoclonal antibodies, COVID vaccines, and antiviral infection drugs. Through the joint efforts of Etana and its partners, we believe that the company will be able to provide high-quality and affordable Chinese innovative drugs to Indonesia, Southeast Asia and even the Islamic world."Legend Capital has been firmly positioned to invest systematically in the field of innovative medicine. Adhering to the investment philosophy of "Global Vision, Chinese Insights", Legend Capital is looking for truly internationally competitive technologies and teams to solve the unmet clinical needs; many of its portfolio companies have been listed on A-share or H-share successfully, such as Kawin Technology (688687.SH), Innovent Biologics (01801.HK), Hbm (02142.HK), Recbio Technology (2179.HK). At the same time, we also made investments in segment-leading companies such as GluBio Pharmaceutical, Ribo Life Science, PegBio, Exegenesis Bio, Lynk Pharmaceuticals and Innostellar Biotherapeutics. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Legend Capital Portfolio: Japan’s NO.1 VTuber Operator ANYCOLOR Lists on the Tokyo Stock Exchange

HONG KONG, Jun 9, 2022 - (ACN Newswire via SEAPRWire.com) - On June 8th 2022, Legend Capital's portfolio company ANYCOLOR, a leading Virtual YouTuber (VTuber) management company in Japan, was listed on the Tokyo Stock Exchange. At the market close today, ANYCOLOR's share price rose more than 3 times compared to the issue price and its market capitalization exceeded 165.2 billion yen (about 1.239 billion US dollars).From left are Itochu Manager Takaki Yasuhiro, ANYCOLOR CEO Tazumi Riku, ANYCOLOR CFO Taurui Shinya and Legend Capital Managing Director Joon Sung Park.Established in May 2017, ANYCOLOR was founded by Tazumi Riku who was at that time a student at Waseda University in Japan. The company officially announced the launch of a VTuber project "NIJISANJI" in January 2018 as one of the first major VTuber agencies in Japan. After years of continued success, ANYCOLOR as of today is managing around 200 VTubers with over 35.72 million fans, making it the largest VTuber operator in Japan.According to ANYCOLOR's IPO Prospectus, in 2021 revenue reached 7.63 billion yen and operating income of 1.45 billion yen. This is over 100% growth from 3.5 billion yen revenue and 42.3 million yen operating income in 2020. Revenue in 2022 is expected to reach 13.2 billion yen while operating income is expected to grow to 3.7 billion yen. With the introduction of Japan partner ITOCHU Corporation, Legend Capital led ANYCOLOR's Series B financing round in April 2020.Joon Sung Park, Managing Director of Legend Capital, said: "Virtual YouTuber is a concept that Japan pioneered and this is a model that can scale outside of Japan because VTubers are not bound by physical limitations, and many of them engage in activities that are unconstrained by their real-world identity. ANYCOLOR is very unique because their focus on livestreams set its members apart from other early VTubers who primarily made pre-recorded videos. Based on Nijisanji's initial success in Japan, ANYCOLOR expanded its business to China, Korea, Indonesia, as well as English-language branches targeting a global audience. VTuber's popularity began to expand internationally through their appeal to the existing animation and cartoon fandom. Going forward, as 2D/3D technology will become more sophisticated, I firmly believe that ANYCOLOR's potential of becoming the internationally recognized leading platform for VTubers and animated influencers, who target worldwide audiences."In China, ANYCOLOR has established a joint venture with Legend Capital's portfolio company Bilibili, a leading video and contents sharing platform in China and most of NIJISANJI's VTubers are active on the Bilibili platform. ANYCOLOR's VTubers started to broadcast livestreaming through Bilibili's platform and was able to successfully operate its Chinese VTuber group "VirtuaReal Project''. Legend Capital also invested in HYBE in early 2016, the management agency of K-pop sensation BTS, and one of the world's "100 Most Influential Companies" as named by Time magazine. Korea's entertainment giant HYBE became the first in the K-pop industry to record 1 trillion won ($839.4 million) in sales in 2021. The unprecedented 100 times revenue growth from 2015 to 2021 was fueled by the agency's effort to build an internal distribution platform, various strategic initiatives for global IP expansion. It also acquired Ithaca Holdings, a well-known US based entertainment agency that manages popular artists like Justin Bieber, Ariana Grande and J Balvin, which helped HYBE to diversify its revenue stream.As an active investor, Legend Capital shared HYBE's growth history and its monetization diversification efforts to ANYCOLOR management team. In addition, Legend Capital introduced the CEO of HYBE to the CEO of ANYCOLOR to share HYBE's experience, and discuss potential cooperation in the future."ANYCOLOR's successful listing under the current capital market situation is not only about fundraising but also about introducing ANYCOLOR to the public and showing a more interesting world of VTuber to the upcoming new generation. Legend Capital will continue to focus on cross-border investment opportunities in Japan, Korea, Southeast Asia and other countries, to explore more investment opportunities in emerging industries, especially in technology, consumption, and contents. We will also continue to utilize our comprehensive resources derived from our existing domestic and international portfolios, to provide value-added services for our portfolio companies." Joon Sung Park added.Legend Capital is an independent and seasoned fund manager with deep roots in China and long coverage of local Chinese investment opportunities stemming from the strong innovation power in the country. With over two decades of expertise, Legend Capital has cultivated profound understanding of the technology and innovation drives of China, accumulated rich resources around industries, and built a powerful portfolio ecosystem. It is now recognized as a valuable partner for overseas investors and enterprises to access the market.For overseas investors, Legend Capital can provide support on knowledge of China's technology innovation and access to technology investment opportunities for sustainable returns. For overseas enterprises, Legend Capital can help expand business on the Chinese market, and bridge key resources in China such as R&D and supply chain, for expedited value creation. Guided by such approach, Legend Capital has made a number of successful investments in Japan, Korea, Southeast Asia, and India.On the other hand, by leveraging its "China Insights", Legend Capital also helps portfolio companies and entrepreneurs in China to "go global" and achieve strategic objectives across the border by integrating overseas resources and opportunities, helping portfolio companies to respond to complex changes in global industry landscape, and meanwhile generating new investment opportunities. Legend Capital has invested numerous successful foreign companies: HYBE (KOSPI.A352820), world's leading entertainment company in Korea; Zinus (KOSPI.A013890), the largest mattress brand in Amazon; DEXTER (KOSDAQ.A206560), Korea's leading movie production and VFX company; NexImmune (NASDAQ: NEXI), the global next-generation immunomodulatory cell therapy company; Axonics (NASDAQ: AXNX), the global developer of new implantable neuromodulation technologies; Singular Genomics (NASDAQ: OMIC), the leading company in NGS testing; Lunit, the global leading AI medical diagnosis company; Mathpresso, the largest education technology company in Japan, Korea, and Southeast Asia; Vedantu, India's largest K12 Online tutoring company; and Akulaku, the leading fintech company in Southeast Asia. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

宏光半导体公布股东之禁售承诺

HONG KONG, Jun 7, 2022 - (亚太商讯 via SEAPRWire.com) - 宏光半导体有限公司（「宏光半导体」，连同其附属公司统称「集团」；股份代号：6908.HK）欣然宣布集团之两位股东，包括主要股东GSR Capital Special Opportunity Fund L.P.（「GSR」）以及策略性股东Great Ocean Prime Holding Limited（「Great Ocean」），自愿决定于2024年5月前将不会出售所持集团的股份。此外，Great Ocean自愿决定于2022年及2023年每年将目前所持有的24,000,000股份之其中8,000,000股拨作奖励及激励集团核心管理人员。此等举措均足证股东对集团之长远价值及业务发展充满信心。集团主要股东之一的GSR为获豁免有限合伙企业，持有集团56,000,000股股份；而GSR的注资总额分别由Golden Sand Capital Ltd（由伍伸俊先生全资拥有的公司，并为GSR的普通合伙人）及伍伸俊先生（为GSR的有限合伙人，同时亦为集团全球战略咨询委员会主席兼核心管理人员）各持有50%。鉴于第三代半导体氮化镓（「GaN」）的发展潜力及其应用场面庞大，宏光半导体凭借其在发光二极管（「LED」）灯珠业务之丰富经验，近年致力把握机遇并加快扩展业务至GaN相关产品的设计、开发、制造、分包服务及销售。集团积极与多家企业达成战略合作，且投资多家世界龙头企业以加快突破GaN核心关键技术，同时亦成功聘请多位半导体专家加入其团队，从而加强及推进GaN业务发展。集团早前与中国泰坦能源拟就中国及香港之快速充电桩技术推广及产品销售进行合作，开发新能源生态圈之快速充电领域。集团管理层衷心感谢GSR以及Great Ocean对其的大力信任。两家公司的决定展现了彼等对集团的稳健业务策略及发展投下信心的一票。凭借半导体行业庞大的机遇和市场需求，加上国家政策的支持，集团锐意发展成为集研发、制造、封测及销售为一体的GaN全产业链企业。宏光半导体将持续推行既定的业务策略以把握市场机遇，提升持份者价值的同时实现长期可持续增长，并予以股东最佳的回报。关于宏光半导体有限公司宏光半导体有限公司（6908.HK）主要在中国从事半导体产品，包括发光二极管（「LED」）灯珠、新一代半导体氮化镓（「GaN」）芯片、GaN器件及其相关应用产品以及快速充电产品的设计、开发、制造、分包服务及销售。凭借多年来在LED制造方面的行业专业知识，集团致力加快步伐研发及拓展GaN相关产品的应用，矢志成为一间集芯片设计、制造生产及销售的半导体领先企业，并提供具有更高效率及更具竞争力系统成本的整体解决方案。有关更多资料，请浏览：www.hg-semiconductor.com Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares

HONG KONG, Jun 2, 2022 - (ACN Newswire via SEAPRWire.com) - On June 1, 2022, TOT BIOPHARM (Stock code: 1875. HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and Centerlab agreed to subscribe for 116,250,000 and 33,750,000 shares of TOT BIOPHARM, respectively, at a subscription price of HK$3.15 per share (Premium issuance based on the past 5 trading days) , with a total of 150,000,000 shares, accounting for approximately 24.38% of the company's issued capital as of the date of this announcement. After the completion of the subscription agreement, assuming that all outstanding share options under the company's Pre-IPO Share Option Scheme will not be exercised before completion, the shareholding ratio of Vivo Suzhou Fund and Centerlab will reach approximately 28.68% and 28.66%.In recent years, TOT BIOPHARM has accelerated its strategic adjustment, strengthened its competitive advantage in the antibody conjugated drugs (ADC) field, and facilitated the construction of an industry-leading ADC one-stop commercialization platform. The company has made every effort to expand its one-stop innovative drug CDMO business, achieving breakthrough results and an ever-growing business scale. This business has already become a new engine for corporate growth.The net proceeds from the Subscriptions have amounted to HK$470 million (approximately RMB 400 million), which will improve corporate liquidity, expand the capital base, optimize the capital structure, and provide support for corporate long-term growth. The company intends to apply the proceeds to: further expand CDMO business and strengthen project cooperation with domestic and foreign pharmaceutical companies; promote the continuous construction of global R&D centers, improving ADC commercialization capacities, thereby improving product cost-effectiveness; complete the phase III clinical trial of TAA013and etc.; carry out production and marketing of Pusintin, Tazian, and Megaxia, etc.Mr. Fu Shan, Chairman of TOT BIOPHARM, Managing Partner, Global Co-CEO and Asia CEO of Vivo Capital LLC, highlighted: "This transaction is another major milestone of TOT BIOPHARM development, which symbolizes its clear strategic planning and business performance have been highly recognized by shareholders. Over the past years, the management team of the company has always concentrated on the advantages of core competencies, optimized resource allocation, and built a differentiated pathway to create a domestically leading and internationally competitive ADC platform. They have also actively expanded CDMO business and established a commercialization platform with great competitive edges and industrial value, showing strong potential and sustainability, which gains shareholders and the board of directors' confidence in the company's future development!"Dr. Liu Jun, CEO of TOT BIOPHARM, expressed: "It is a great honor to gain the strong support and recognition of our two major shareholders, Vivo Capital and Centerlab, during the critical period of us re-setting corporate priorities on commercialization and strategic adjustment with ADC as the core! By far, our strategic transformation and up-gradation to ADC CDMO have yielded remarkable results. This capital increase will further enhance our capital strength and provide financial support for corporate sustainability. In the upcoming days, we will continue take efforts to optimize capital structure, establish a diversified and sustainable business model, as well as to enhance the comprehensive strength of process development, accelerate the ADC commercialization process, and create a new engine for CDMO business growth, thereby strengthening the corporate earning capacity, and creating bountiful returns for shareholders and investors."About Vivo Suzhou Fund and Other Funds Managed by Vivo Capital LLCVivo Suzhou Fund is a limited partnership established in the PRC managed by Vivo Equity Investment Management (Shanghai) Co., Ltd. , a private equity fund manager registered with the Asset Management Association of China which is directly wholly-owned and controlled by Vivo Capital LLC. Vivo VIII Funds, which are also funds managed by Vivo Capital LLC, have been shareholders of the Company since December 2015. Vivo Capital LLC's predecessor was founded in the United States in 1996. Vivo Capital LLC was incorporated in the State of California of the United States in 2005, and is an investment adviser registered with the United States Securities and Exchange Commission. Spanning private equity, public equity and venture capital, it is a global healthcare investment firm that focuses on finding and building value in healthcare companies in the United States and Greater China. It invests in both public and private healthcare companies through funds managed by it or its affiliate, including Vivo Suzhou Fund and Vivo VIII Funds, among others. In terms of assets under management (AUM), as of 31 December 2021, Vivo Capital LLC managed over US$6.4 billion in client assets on a discretionary basis.About CenterlabCenterlab was incorporated in Taiwan in 1959 and its shares were listed on the Taipei Exchange in 2003 (stock code: 4123). It is Taiwan's largest manufacturer of oral liquid pharmaceuticals, with a market share of about 70%. Its products are mainly oral solutions, including syrups, suspensions, emulsions and other dosage forms. It also engages in new drug research and development, active pharmaceutical ingredients, minimally invasive medical devices and other businesses through investments in other corporations. In recent years, Centerlab is known as the "Biotech Industrial Bank" in Taiwan for its track record of incubating or investing in various biotech and related companies listed or to be listed on the Stock Exchange or the Taipei Exchange (including the Company) and fostering their growth and development. As of 31 December 2021, Centerlab had total assets of NT$30.4 billion (equivalent to approximately US$1.1 billion). Centerlab (together with its former associate BioEngine Venture Capital Inc. and/or current associate BioEngine Technology) has been a shareholder of the Company since January 2011.Forward-Looking StatementsThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to TOT BIOPHARM, are intended to identify certain of such forward-looking statements. TOT BIOPHARM does not intend to update these forward-looking statements regularly.These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of TOT BIOPHARM with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond TOT BIOPHARM's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, TOT BIOPHARM's competitive environment and political, economic, legal and social conditions.TOT BIOPHARM, the Directors and the employees of TOT BIOPHARM assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

维梧苏州基金及晟德大药厂认购东曜药业股份

HONG KONG, Jun 1, 2022 - (亚太商讯 via SEAPRWire.com) - 东曜药业（股票代码：1875.HK）宣布公司与维梧苏州基金及晟德大药厂订立股份认购协议。根据协议，维梧苏州基金与晟德大药厂将分别认购东曜药业配售股份116,250,000股及33,750,000股，认购价每股 3.15港元（依据过往5个交易日溢价发行），合共150,000,000股，占本公告日期公司已发行股本约24.38%。本次认购协议完成后，假设公司首次公开发售前购股权计划下未获行使购股权于完成前均不会获行使，维梧苏州基金与晟德大药厂持股占比将分别达约28.68%及28.66%。近年以来东曜药业加速战略调整，强化公司在抗体偶联药物（ADC）领域的竞争优势, 并加快建设行业领先的ADC一站式产业化平台；全力拓展一站式创新药CDMO业务，目前已经取得突破性成果，业务规模大幅增长，成为公司发展新引擎。本次股份认购募集资金总额达4.7亿港元（约合人民币4亿元），该款项将改善公司的流动资金，扩大公司资本基础，优化公司资本架构，为公司的长期发展提供支持。资金拟重点用于：进一步拓展CDMO业务，加强与国内外制药公司的项目合作；推动全球研发中心持续建设，提升ADC商业化生产能力，从而提升成本效益；完成TAA013的III期临床试验，以及TAE020、TAC020等在研药物的临床前及临床试验；开展朴欣汀®、替至安®及美适亚®的商业化生产和市场营销等。东曜药业董事长、维梧资本管理合伙人、全球联席CEO及亚洲区CEO付山先生表示：“本次交易是东曜药业发展道路上的又一重大里程碑，其清晰的战略规划和良好的业绩表现获得了股东的高度认可。近年来，东曜药业管理团队不断聚焦核心竞争优势、优化资源配置，坚定差异化发展之路，打造了国内领先、具有国际竞争力的ADC全产业链平台，积极拓展CDMO业务，搭建了极具竞争优势和产业价值的商业化生产平台，展现出强劲、持续的发展潜力，公司股东及董事会对公司未来发展充满信心！”东曜药业首席执行官刘军博士表示：“非常荣幸能够在公司提升商业化发展及以ADC为核心进行战略调整的关键时期获得两大股东维梧资本和晟德大药厂的鼎力支持和认可！东曜药业向ADC CDMO的战略转型升级已取得显著成果，通过本次增资，将进一步充实公司的资本实力，为公司持续发展提供资金支持。未来，东曜药业将继续优化资本结构，建立多元及可持续发展模式；不断提升工艺开发综合实力，加速ADC商业化产能升级，打造CDMO业务成长新引擎，从而强化公司自身造血能力，以期为广大股东和投资人创造丰厚回报。”关于维梧苏州基金及Vivo Capital LLC管理的其他基金维梧苏州基金为一间于中国成立由一间于中国证券投资基金业协会注册的私募基金管理人维梧股权投资管理（上海）有限公司（由Vivo Capital LLC直接全资拥有及控制）管理的有限合伙企业。Vivo VIII Funds亦为 Vivo Capital LLC管理的基金，自2015年12月以来为本公司的股东。Vivo Capital LLC的前身于1996年于美国成立。Vivo Capital LLC于2005年于美国加利福利亚州注册成立，为于美国证券交易委员会注册的投资顾问。其为一家全球医疗保健投资公司，涉猎广泛，涉及私募股权、上市股权及风险投资，专注于发现及增值美国及大中华的医疗保健公司。其透过自身或其联属公司（包括维梧苏州基金及Vivo VIII Funds）管理的基金投资上市及私人医疗保健公司。就资产管理规模(AUM)而言，截至2021年12月31日，Vivo Capital LLC获全权委托管理的客户资产逾64亿美元。关于晟德大药厂晟德大药厂于1959年于台湾注册成立，其股份于2003年在证券柜台买卖中心上市（股份代号：4123）。晟德大药厂为台湾最大口服液剂制造商，市占率约70%，产品以内服液剂为主，包含糖浆剂、悬浮剂、乳剂等剂型，并透过转投资从事新药研发、原料药、微创医疗器材等其他业务。近年来，晟德大药厂因其孵化或投资于联交所或证券柜台买卖中心已上市或将上市的多个生物技术及相关公司（包括本公司）以及促进其增长及发展的往绩记录而成为台湾知名的「生技工业银行」。截至2021年12月31日，晟德大药厂资产总值为新台币304亿元（相当于约11亿美元）。晟德大药厂（连同其前联系人BioEngine Venture Capital Inc.及／或现时联系人玉晟管顾）自2011年1月以来一直为本公司股东。前瞻性声明本新闻稿中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用“预期”、“相信”、“预测”、“期望”、“打算”及其他类似词语进行表述时，凡与本公司有关的，均属于前瞻性表述。本公司并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本公司管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司、本公司董事及雇员代理概不承担 (a) 更正或更新本网站所载前瞻性表述的任何义务;及 (b) 若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOP BIOPHARM Shares

HONG KONG, Jun 1, 2022 - (ACN Newswire via SEAPRWire.com) - TOT BIOPHARM (Stock code: 1875. HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and Centerlab agreed to subscribe for 116,250,000 and 33,750,000 shares of TOT BIOPHARM, respectively, at a subscription price of HK$3.15 per share (Premium issuance based on the past 5 trading days) , with a total of 150,000,000 shares, accounting for approximately 24.38% of the company's issued capital as of the date of this announcement. After the completion of the subscription agreement, assuming that all outstanding share options under the company's Pre-IPO Share Option Scheme will not be exercised before completion, the shareholding ratio of Vivo Suzhou Fund and Centerlab will reach approximately 28.68% and 28.66%.In recent years, TOT BIOPHARM has accelerated its strategic adjustment, strengthened its competitive advantage in the antibody conjugated drugs (ADC) field, and facilitated the construction of an industry-leading ADC one-stop commercialization platform. The company has made every effort to expand its one-stop innovative drug CDMO business, achieving breakthrough results and an ever-growing business scale. This business has already become a new engine for corporate growth.The net proceeds from the Subscriptions have amounted to HK$470 million (approximately RMB 400 million), which will improve corporate liquidity, expand the capital base, optimize the capital structure, and provide support for corporate long-term growth. The company intends to apply the proceeds to: further expand CDMO business and strengthen project cooperation with domestic and foreign pharmaceutical companies; promote the continuous construction of global R&D centers, improving ADC commercialization capacities, thereby improving product cost-effectiveness; complete the phase III clinical trial of TAA013and etc.; carry out production and marketing of Pusintin, Tazian, and Megaxia, etc.Mr. Fu Shan, Chairman of TOT BIOPHARM, Managing Partner, Global Co-CEO and Asia CEO of Vivo Capital LLC, highlighted: "This transaction is another major milestone of TOT BIOPHARM development, which symbolizes its clear strategic planning and business performance have been highly recognized by shareholders. Over the past years, the management team of the company has always concentrated on the advantages of core competencies, optimized resource allocation, and built a differentiated pathway to create a domestically leading and internationally competitive ADC platform. They have also actively expanded CDMO business and established a commercialization platform with great competitive edges and industrial value, showing strong potential and sustainability, which gains shareholders and the board of directors' confidence in the company's future development!"Dr. Liu Jun, CEO of TOT BIOPHARM, expressed: "It is a great honor to gain the strong support and recognition of our two major shareholders, Vivo Capital and Centerlab, during the critical period of us re-setting corporate priorities on commercialization and strategic adjustment with ADC as the core! By far, our strategic transformation and up-gradation to ADC CDMO have yielded remarkable results. This capital increase will further enhance our capital strength and provide financial support for corporate sustainability. In the upcoming days, we will continue take efforts to optimize capital structure, establish a diversified and sustainable business model, as well as to enhance the comprehensive strength of process development, accelerate the ADC commercialization process, and create a new engine for CDMO business growth, thereby strengthening the corporate earning capacity, and creating bountiful returns for shareholders and investors."About Vivo Suzhou Fund and Other Funds Managed by Vivo Capital LLC Vivo Suzhou Fund is a limited partnership established in the PRC managed by Vivo Equity Investment Management (Shanghai) Co., Ltd. , a private equity fund manager registered with the Asset Management Association of China which is directly wholly-owned and controlled by Vivo Capital LLC. Vivo VIII Funds, which are also funds managed by Vivo Capital LLC, have been shareholders of the Company since December 2015. Vivo Capital LLC's predecessor was founded in the United States in 1996. Vivo Capital LLC was incorporated in the State of California of the United States in 2005, and is an investment adviser registered with the United States Securities and Exchange Commission. Spanning private equity, public equity and venture capital, it is a global healthcare investment firm that focuses on finding and building value in healthcare companies in the United States and Greater China. It invests in both public and private healthcare companies through funds managed by it or its affiliate, including Vivo Suzhou Fund and Vivo VIII Funds, among others. In terms of assets under management (AUM), as of 31 December 2021, Vivo Capital LLC managed over US$6.4 billion in client assets on a discretionary basis.About Centerlab Centerlab was incorporated in Taiwan in 1959 and its shares were listed on the Taipei Exchange in 2003 (stock code: 4123). It is Taiwan's largest manufacturer of oral liquid pharmaceuticals, with a market share of about 70%. Its products are mainly oral solutions, including syrups, suspensions, emulsions and other dosage forms. It also engages in new drug research and development, active pharmaceutical ingredients, minimally invasive medical devices and other businesses through investments in other corporations. In recent years, Centerlab is known as the "Biotech Industrial Bank" in Taiwan for its track record of incubating or investing in various biotech and related companies listed or to be listed on the Stock Exchange or the Taipei Exchange (including the Company) and fostering their growth and development. As of 31 December 2021, Centerlab had total assets of NT$30.4 billion (equivalent to approximately US$1.1 billion). Centerlab (together with its former associate BioEngine Venture Capital Inc. and/or current associate BioEngine Technology) has been a shareholder of the Company since January 2011.Forward-Looking StatementsThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to TOT BIOPHARM, are intended to identify certain of such forward-looking statements. TOT BIOPHARM does not intend to update these forward-looking statements regularly.These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of TOT BIOPHARM with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond TOT BIOPHARM's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, TOT BIOPHARM's competitive environment and political, economic, legal and social conditions.TOT BIOPHARM, the Directors and the employees of TOT BIOPHARM assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

MC and Morgenrot Enter into Capital and Business Alliance

TOKYO, May 20, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Corporation (MC) and Morgenrot Inc. (Morgenrot) are pleased to announce that we have entered into a capital and business alliance, our aim being to jointly develop distributed computing services for customers in Japan and throughout ASEAN. MC is one of Japan's leading sogo shosha (general trading companies), while Morgenrot is an engineering-centric startup company which provides cloud-based distributed computing solutions and green data centers powered by renewable energy. At the core of Morgenrot's capacity for software development is its proprietary distributed processing technology, "Excalibur," which leverages the latest GPU (Graphics Processing Unit) technology based hardware systems to add value to its cloud-based services. Morgenrot's exceptional processing capabilities are deployed by the front lines of research and development in numerous high-tech fields, including ultra-high-resolution 3D rendering, simulations, AI, machine- and deep-learning systems, and so on. Furthermore, by applying its knowledge and experience of GPU servers, Morgenrot integrates GPU-based high-performance server systems in mobile containers powered by renewable and surplus energy to realize green data centers. Keen to help society realize a digital infrastructure eco-system that is conscious of both our needs and those of our planet, Morgenrot is making its clean processing capabilities available at affordable prices. MC has also been putting its assets to good use in digital infrastructure. Here in Japan, the sogo shosha is applying its multi-industry know-how and expertise to develop hyperscale data centers. Always on the lookout for ways to promote digital (DX) and energy (EX) transformations that take advantage of the MC Group's collective capabilities, MC is confident that this alliance with Morgenrot will foster progress that ultimately leads to new business opportunities. This progress includes the construction of distributed data-center networks capable of processing huge volumes of data, as well as the development and installation of edge computing infrastructure that will make real-time and low-latency processing possible. Both of our companies are investigating ways to jointly conceive products and services not only here in Japan, but also in international markets, with our initial focus being the ASEAN region. Prior to entering into this capital and business alliance, we commenced discussions on the provision of high-power computing services in Singapore. By supporting the city state's DX initiative, this business should complement Singapore's status as one of the world's leading developers of smart cities, and it also has good potential for growth, as it can be adapted for other ASEAN countries in the future.Mitsubishi CorporationTelephone:+81-3-3210-2171 Facsimile:+81-3-5252-7705 Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Soluna Raises $35M from Spring Lane Capital to Build Green Data Centers for Crypto, Machine Learning

ALBANY, NY, May 12, 2022 - (ACN Newswire via SEAPRWire.com) - Soluna Holdings, Inc. ("SHI" or the "Company"), (NASDAQ: SLNH), the parent company of Soluna Computing, Inc. ("SCI"), secured $35 million in project financing to develop green data centers co-located with renewable energy assets. Spring Lane Capital, a private equity firm, invested private funds in Soluna as a part of their strategy focused on hybrid project capital for sustainability solutions in the energy, food, water, waste and transportation industries. The capital will help develop three behind-the-meter (BTM) projects designed to convert wasted renewable energy into clean computing services such as bitcoin mining and artificial intelligence."Soluna is the only true green bitcoin company we've yet seen," said Rob Day, Spring Lane Capital Partner and Co-Founder. "Going after wasted renewable energy 'spilled power' is a compelling solution and fixes both bitcoin's climate problem and wind power's grid problem."Michael Toporek, CEO of Soluna Holdings, Inc. said, "Consistent with our previously articulated strategy, we continue to pursue opportunities that we believe enable us to optimize our cost of capital. The Spring Lane Capital approach helps us develop a mature repeatable model that can be scaled."The first of the three projects, Dorothy, named in honor of African American mathematician and human computer Dorothy Vaughan, is expected to be energized later this summer and coincide with the launch of a local STEM program. The Dorothy project is a 100 MW data center with a 50 MW initial phase, connected to a Texas wind farm that produces more electricity than the grid can consume. Soluna's data center is currently estimated to create between 25 to 50 highly skilled jobs for technicians, security and electrical staff.The other two projects funded by the new capital will come from Soluna's robust pipeline.John Belizaire, CEO of Soluna Computing, Inc., said, "We are honored to have a pioneering sustainability project finance firm like Spring Lane Capital back our vision. Our model of leveraging excess clean energy to generate low-cost computing is the future of green bitcoin mining and green data centers."Spring Lane Capital has a successful track record helping sustainable technology companies raise capital to build flagship projects. Their 'hybrid project capital' approach provides project equity along with additional growth capital.Added Day: "Soluna is driving demand for clean power by giving a floor price and improving the bottom line of the renewable power partners they work with. The ultimate result is more wind farms and solar farms that would not otherwise be built."At power plants like the wind farm where the Dorothy project is under construction, excess energy is wasted when the grid becomes overloaded or demand is too low. Soluna's scalable solution allows every excess megawatt to be used for batch-oriented, computing-intensive processes, such as cryptocurrency mining and machine learning. Additionally, flexible demand consumers help stabilize the grid by preventing power overload, which can otherwise lead to blackouts and grid malfunction.Last month, Soluna Holdings (SCI's Computing's parent company), sold its Albany-based MTI Instruments subsidiary for $10.75 million, expanding its focus on helping the modern grid absorb more renewable energy through flexible green data centers.About Soluna Holdings, Inc.Soluna Holdings, Inc. (Nasdaq: SLNH), which operates through its subsidiary, Soluna Computing, Inc. is the leading developer of green data centers that convert excess renewable energy into global computing resources. Soluna builds modular, scalable data centers for computing-intensive, batchable applications such as cryptocurrency mining, AI and machine learning. Soluna provides a cost-effective alternative to battery storage or transmission lines. Up to 30% of the power of renewable energy projects can go to waste. Soluna's data centers enable clean electricity asset owners to 'Sell. Every. Megawatt.' For more information about Soluna, please visit solunacomputing.com or follow us on LinkedIn and Twitter.Investor Relations:Kirin Smith, President PCG Advisory, Inc.646.823.8656Ksmith@pcgadvisory.comMedia contact:Bridgette Borst Ombres, Tigercomm(304) 546-3788bombres@tigercomm.us Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Legend Capital’s Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China

HONG KONG, Apr 24, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics, announced that the clinical trial application of its product LX101 injection for the treatment of patients with Rpe65 biallelic mutation-associated inherited retinal degenerations (IRD) was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China.Founded in 2020, Innostellar Biotherapeutics is a biopharmaceutical startup company focusing on gene therapy for innovative drug discovery, manufacture, and commercialization. Its core team consists of scientists and professionals from world-renowned institutions and biopharmaceutical companies. Since its establishment, Innostellar Biotherapeutics has been working closely with top-notch clinical scientists from hospitals around China and focusing on urgent needs of patients with genetic diseases and chronic diseases. The company has laid a firm foundation in the proof-of-concept development of a number of pipelines, process technology development, and quality system.Inherited retinal degeneration (IRD) caused by the Rpe65 gene mutation is a typical rare disease that leads to blindness and has no effective treatment in the past. As a breakthrough technology, gene therapy provides the possibility to compensate or fix defective genes and fundamentally reinstate the normal gene functions. According to the early data of related products abroad, the treatment helped IRD patients in vision improvement and maintained therapeutic qualities for long term.Dr. Fenghua WANG, CEO of Innostellar Biotherapeutics, said: "This is an important milestone for our company since its founding. LX101 has gradually demonstrated its therapeutic potential since we cooperated with the National Clinical Research Center for Eye Diseases in 2021 to carry out the first IIT clinical research of IRD gene therapy in China. We expect LX101 to benefit more patients with the therapeutic breakthroughs and maximal treatment effects. We also expect gene therapy to provide effective solutions for improving life of people with genetic and chronic diseases.Innostellar Biotherapeutics was co-founded by Legend Capital and its founding team. As the earliest investor in the company, Legend Capital and the Innostellar team worked together on company structure organization design, strategy decision, and pipeline planning. With constant support to the development of Innostellar Biotherapeutics, Legend Capital has backed the company in its two rounds of financing. Legend Capital has long been committed to systemic investment in the field of innovative medicine. Adhering to the investment philosophy of "Global Vision, Chinese Perspective", Legend Capital is looking for truly internationally competitive technologies and teams to solve the unmet clinical needs; many of its portfolio companies have listed on A-share or H-share successfully, such as Kawin Technology (688687.SH), Innovent Biologics (01801.HK), Harbour BioMed (02142.HK), and Recbio Technology (02179.HK). At the same time, Legend Capital also have made investments in leading companies in the segment like Suzhou Ribo Life Science, Pegbio, Exegenesis Bio, Lynk Pharmaceuticals, and Glubio. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Waterdrip Capital to Become the Lead Investor of TRUE on the Asian Market

NEW YORK, NY, April 20, 2022 – (SEAPRWire) – TRUE joins the pool of interest of Waterdrip Capital which becomes its lead investor on the Asian market. TRUE is an ecosystem to create and deliver next gen NFT utilities to GameFi industry and everyday life. The company is set to grow in a decentralized multi-chain infrastructure to guide brands, developers and users to the world of Web 3.0. “TRUE helps traditional brands with transition from web2 to web3 world, and the experience of its team members will assure the success,” said Yushan Zheng, Co-founder, Waterdrip Capital. Waterdrip Capital is a foundation started in 2017 by the most forward-thinking Chinese blockchain pioneers as an international investment institution focusing on blockchain industry. The company will become a solid backup for TRUE to provide the project with the mighty take-off and introduction to the top-tier funds, exchanges and KOLs. Waterdrip actively invests in various fields of the blockchain ecosystem, including public chains, protocol layers and applications, especially Polkadot, DPOS ecosystem, COSMOS/IRISnet ecosystem, Defi applications, DAO applications, in total more than 50 blockchain projects worldwide. Such firm support will help TRUE to accumulate some prominent partners on the way to its mission – to unleash the potential of NFT technology and expand its functionality for widespread use. “On every pitch session, Waterdrip Capital is always presented as one of the top smart investors. This foundation has always been distinguished by its openness, friendliness and strong support. I am incredibly excited to have them as our lead investor in Asia! This is one of the best foundations you can imagine. Thank you guys for your trust! I am sure, there is a long, fruitful and interesting journey ahead of us,” said Dan Andrian, CEO, TRUE. Stay tuned for the updates on the Waterdrip Capital and TRUE cooperation: TRUE Social Links TRUE Telegram Channel: https://t.me/true_ecosystem TRUE Telegram Group: https://t.me/true_community TRUE Twitter: https://twitter.com/TRUE_Ecosystem TRUE Discord: https://discord.gg/xUPvjawmUa TRUE Linkedin: https://www.linkedin.com/company/truefuture Waterdrip Capital Social Links Waterdrip Telegram: https://t.me/waterdripspaceship Waterdrip Twitter: https://twitter.com/waterdripfund Waterdrip Linkedin: https://www.linkedin.com/company/waterdrip-capital Media Contact Brand: TRUE Contact: Media team E-mail: pr@truefuture.io Website: https://truefuture.io SOURCE: TRUE The article is provided by a third-party content provider. SEAPRWIRE makes no warranties or representations in connection therewith. Any questions, please contact cs@SEAPRWIRE.com Sectors: Top Story, Daily News SEAPRWIRE (www.seaprwire.com) offers newswire service in Southeast Asia (Indonesia, Thailand, Vietnam, Singapore, Malaysia, Philippines & Hong Kong )

Read More
Posted on

High West Capital Partners Ranks as One of the Best Lender/Financing Companies in Singapore

Best Lending/Financing Companies and Startups in Singapore (2021) – High West Capital Partners Singapore – A recent article showcasing the best Singapore-based lending/financing companies selected High West Capital Partners for its exceptional performance and established brand. The Daily Finance article author stated, “These startups and companies are taking a variety of approaches to innovating the Lending//Financing industry.” Best Lending/Financing Companies and Startups in Singapore (2021) by Daily Finance (df.media) These are the Best Lending/Financing Companies and Startups in Singapore (2021) High West Capital Partners is a leading private investment firm based in Singapore and Hong Kong. Over the last 20 years, it has established itself as a significant force in South America, Europe, and the Asia Pacific, focusing on global structured finance and special situations. The firm’s primary objective is to provide immediate funding to clients who need liquidity. About High West Capital Partners High West Capital Partners provides custom liquidity solutions to institutional investors, mutual funds, family offices, publicly listed companies, corporate officers, and directors. It provides innovative financing structures that its competitors cannot offer due to its pool of long-term capital. Media Contact High West Capital Partners Hong Kong: +852 3002 4462 Singapore: +65 3105 1295 deals@highwestcapitalpartners.com pr@highwestcapitalpartners.com R91, 3rd Floor, Eton Tower, Eton Tower, 8 Hysan Ave., Causeway Bay, Hong Kong https://highwestcapitalpartners.com/ SOURCE: High West Capital Partners

Read More
Posted on

Black Spade Capital Launches its First Ever Limited Edition Gift Set with L’OCCITANE en Provence Product

HONG KONG, Apr 11, 2022 - (ACN Newswire via SEAPRWire.com) - This Easter, Black Spade Capital Limited ("Black Spade Capital") is giving the gift of wellbeing to its friends and business partners. This initiative also marks the first ever cross-over of the family office founded by Mr. Lawrence Ho with the leading French beauty and well-being house. Black Spade X L'OCCITANE Gift BoxMr. Dennis Tam, President and CEO of Black Spade Capital, said, "It was a rewarding experience to see this idea turn from concept to reality. Black Spade Capital has always had a keen focus on the lifestyle and leisure space. L'OCCITANE, whose wide range of signature products are loved by so many around the world, is undoubtedly one of the most iconic brands in this sector. We enjoyed every bit of the process, from curating this collection to designing the gift set artwork. We put a lot of thought into deciding the theme of the gift set - we are very pleased with the final result and adore the revitalizing scent of this collection which, in my opinion, is particularly fitting for springtime. We believe our exclusive collection, available only in a limited quantity of 250 boxes, will be equally enjoyed by its recipients.""We are very excited about this idea and hope that this meticulously crafted gift set will send our best wishes to our friends and associates - at a time when personal well-being is more important than ever," added Mr. Tam.About Black Spade Capital LimitedBlack Spade Capital Limited ("Black Spade Capital") is an established family office managing the private investments of Mr. Lawrence Ho. Headquartered in Hong Kong, its global portfolio consists of a wide spectrum of cross-border investments as it consistently seeks to add new projects and opportunities to its investment mix. Black Spade Capital's investment strategy maximizes coverage of geographic regions and sectors whilst maintaining a portfolio of diversified asset classes, ranging from equity, fixed income, medical technology, leisure and culture, green energy, real estate to pre-IPO investments. In July 2021, Black Spade Acquisition Co (NYSE: BSAQ), a special purpose acquisition company of which a subsidiary of Black Spade Capital is sponsor, was listed on the New York Stock Exchange.Media Enquiries:Strategic Financial Relations LimitedVicky Lee Tel: +852 2864 4834 Email: vicky.lee@sprg.com.hk Christina Cheuk Tel: +852 2114 4979 Email: christina.cheuk@sprg.com.hk Website: www.sprg.com.hk Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Legend Holdings (3396.HK) Announced 2021 Annual Results

HONG KONG, Apr 1, 2022 - (ACN Newswire via SEAPRWire.com) - According to South China Morning Post, Global market experienced another rock year. The impact of COVID-19 still not got away, the chaos of global supply chain showed that the world still need time to recover; the aftermath of geopolitical factors heavily disturbed the global capital markets, further sparked investor concerns. In such an environment, a comprehensive company with a solid business foundation and years of forward-looking layout tends to have higher risk tolerance, such as Legend Holdings. The company announced its 2021 annual results yesterday, achieving a steady growth.Mr. Li Peng, CEO of Legend Holdings stated: "the company strengthened its foothold in its industries of focus, proactively responded to the impact of the pandemic and various external environmental changes, dynamically modified business strategies and increased investment in technology and innovation. Legend Holdings realized a revenue of RMB489.872 billion, an increase of 17% year-on-year, and a net profit attributable to equity holders of the Company of RMB5.755 billion, an increase of 49% year-on-year. Both revenue and profit hit new high."Continuous Growth Momentum of Industrial Operations Segment, Business Foundation Further ConsolidatedLegend Holdings' sound performance is mainly due to the continuous growth momentum of industrial operations segment, pillar companies in this segment consolidate existing advantages and deepen innovation in all aspects, namely Lenovo, Levima Advanced Materials, Joyvio Group and Banque Internationale a Luxembourg S. A (BIL). In 2021, Lenovo seized the opportunities of global digitalization and intelligent transformation, the three core businesses achieved record-high results and further improvement of profitability, resulting in a net profit attributable to equity holders of Legend Holdings amounted to RMB4.019 billion, an increase of 92% year-on-year. Lenovo has always attached importance to investment in science and technology, and in 2021, it set a goal of "investing an annual average of RMB20 billion in R&D in the next three years and doubling its R&D personnel to no less than 24,000". At present, relevant work is progressing steadily. In the fourth quarter of 2021, it invested RMB3.5 billion, representing a year-on-year increase of 38%.Levima Advanced Materials adhered to its innovation-driven strategy with a 60% year-on-year increase in R&D investment and planned to invest RMB10 billion in the fields of new energy materials and biodegradable materials, some projects have already started. Benefiting from factors such as strong demand for new energy products, improved operational efficiency, and high-end differentiated product strategies, it realized a net profit attributable to equity holders of Legend Holdings of RMB565 million, an increase of 70% year-on-year.Joyvio Group continued to focus on its two main business lines, namely high-end fruit and premium animal protein and turned loss into profit through a series of initiatives during the reporting period. BIL constantly upgraded its business models and in 2021, all of its key business indicators recorded year-on-year growth, CET-1 ratio up to 14.15%, net profit attributable to equity holders of Legend Holdings amounted to RMB873 million, an increase of 35% year-on-year (excluding exchange rate differences).Through the above companies' performance, we can find that in 2021, Legend Holdings has not only solidified the foundation of industrial operations, but also increased investment in technology innovation in line with national strategies, and the future development of the company is expected to be worth looking forward to. Legend Holdings has a tradition of deep involvement in the field of technology and innovation, and this tradition is also fully demonstrated in its industries incubations and investments segment.Growing Industrial Incubations and Investments, Greater Support for Technology Start-upsLegend Holdings has deployed technology start-ups for a long time, and in 2021, Legend Holdings continued to redouble its efforts in investment and financial support regarding scientific and technological innovation.With the background of the government attaching great importance to the development of the semiconductor industry, Legend Holdings has earlier made a strategic investment in the high-tech company Fullhan Microelectronics, which specialized in the design and development of chips, and further increased its holding shares to 15.90% in 2021. Fullhan Microelectronics maintained a high proportion of R&D investment and promoted the improvement and upgrade of product lines. It has developed a complete product line from simulation to digitization and from front end to back end, with its R&D expenditure up by more than 100% over the previous year. In 2021, Legend Holdings and Fullhan Microelectronics jointly founded Hanlian Semiconductor Industry Fund for greater cooperation in the semiconductor industry.Through Legend Capital and Legend Star, Legend Holdings invested in more than 100 new innovative technological projects, covering advanced technology, biomedicine, advanced manufacturing, TMT, and other fields, with 21 of its investee companies entering domestic and overseas capital markets. As of the end of 2021, there were 39 companies invested by Legend Holdings have been selected into the list of national-level Specialized, Fined, Peculiar, and Innovative (SFPI) enterprises. In addition, Legend Holdings and its subsidiaries' businesses have also supported the growth of nearly 200 Chinese SFPI enterprises through supply chain procurement, financial support and professional services.The Legend Holdings' long-term investment in companies with high technological potential shows the insight to future. These actions would provide abundant financial returns and long-term development and will further nurture or establish a range of enterprises to take up leading positions while having excellent profitability in multiple industries and fields, meanwhile make more contributions to the development of innovative technological industries of China in the next step.Comprehensively Strengthening ESG-related InitiativesIn recent years, global warming has led to a variety of environmental problems such as melting glaciers and rising sea levels, which has also aroused the concern of various countries. With the introduction of China's "carbon peaking and neutrality" target last year and the unanimous decision to "accelerate climate action" at the 26th United Nations Climate Change Conference, Environmental, Social and Governance (ESG) has been elevated to a new level, and the capital market is paying more attention to corporate ESG initiatives, which can also highlight corporate values. In 2021, Legend Holdings strengthened and implemented its ESG-related initiatives into daily running continually. Lenovo reduced carbon emissions by 92% over the past decade, selected as a UN Advanced Business Practices case for low carbon practices. In 2021, It also set a goal of achieving net zero carbon emissions by 2050 and actively exports products, services and solutions to help various industries achieve carbon neutrality. Levima Advanced Materials also protected the environment in its business, put vigorous efforts to develop new energy and biodegradable materials, and effectively achieved the objectives of lower energy consumption and greenhouse gas emissions through different initiatives. In terms of ESG investments that have emerged in recent years, Legend Holdings' subsidiaries are also at the forefront. BIL formally became a signature-recognized bank of the United Nations Global Compact and the United Nations Principles for Responsible Banking (UN PRBs) and helped Chinese-invested enterprises successfully issue green bonds. Legend Capital, as the first leading VC/PE institution in China joining United Nations Organization for Responsible Investment, has invested in over 20 "dual-carbon" technology-based enterprises.Looking into future, Mr. Ning Min, chairman of Legend Holdings said: "We have never forgotten our mission of promoting technological innovation, assisting industrial development, and our social responsibility as an international enterprise rooted in China. Facing the future, we will always keep an open mind, a pragmatic style, uphold the entrepreneurial spirit, move forward with courage, and make more positive contributions to the new era with solid achievements on the new journey in the future." Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

High West Capital Partners to Establish Taiwan Equity Base

Following on from Increased Partnership Growth in the Asian Equities Market, High West Capital Partners is Now Establishing a Foothold in Taiwan Singapore, March 16, 2022 - (SEAPRWire) - High West Capital Partners is a leading private investment firm based in Singapore and Hong Kong. Over the last 20 years, it has established itself as a significant force in South America, Europe, and the Asia Pacific, focusing on global structured finance, and special situations. The firm's primary objective is to provide immediate funding to clients who need liquidity. Now they plan on implementing their strategic success in Taiwan. High West Capital Partners' management commented on the company vision to be "committed to funding small and mid-cap companies, often overlooked by larger institutions, to achieve their capital needs and goals. Our proprietary structures can provide the liquidity requirements that companies, management, and shareholders may face in the global equity and debt markets. They can secure funding by HWCP onshore in local currency or offshore to overcome financial hurdles in a timely manner." Commenting on the firm's international expansion, High West Capital Partners stated that, "it requires a unique understanding to deploy funds across multiple sectors in many different frontier and emerging markets. Our pillars of success are supported by our team of seasoned capital market veterans who've managed top investment firms in Singapore, Tokyo, Hong Kong, Dubai, and London. A qualitative edge blended with our quantitative algo models bolster our expansion around the globe." Following their success in the Singapore and Hong Kong market, High West Capital Partners also expanded to a multi-strategy firm focusing on Asia. Their strategy is based on equity arbitrage, global fixed income, cryptocurrency, and structure finance for concentrated shareholdings in public and private companies. About High West Capital Partners High West Capital Partners provides custom liquidity solutions to institutional investors, mutual funds, family offices, publicly listed companies, corporate officers, and directors. High West Capital Partners provides innovative financing structures that their competitors cannot offer due to their pool of long-term capital. Media Contact High West Capital Partners +65 3158 7420 deals@highwestcapitalpartners.com  pr@highwestcapitalpartners.com  68 Robinson Road #12-01 Capital Tower, Singapore 068912 R91, 3rd Floor, Eton Tower, Eton Tower, 8 Hysan Ave., Causeway Bay, Hong Kong https://highwestcapitalpartners.com/ SOURCE: High West Capital Partners The article is provided by a third-party content provider. SEAPRWIRE makes no warranties or representations in connection therewith. Any questions, please contact cs@SEAPRWIRE.com Sectors: Top Story, Daily News SEAPRWIRE (www.seaprwire.com) offers newswire service in Southeast Asia (Indonesia, Thailand, Vietnam, Singapore, Malaysia, Philippines & Hong Kong )

Read More
Posted on

IDG Capital Vietnam Confirms Investment in METAIN to Lead NFT-Empowered Real Estate Trend in Vietnam

Vancouver, Canada, March 7, 2022 – (SEAPRWire) –  IDG Capital Vietnam – the leading Ventures capital with strong focus on high-quality technology startups confirms their investment in METAIN – the first co-investment platform based on blockchain and NFT technology in Vietnam. This partnership is expected to foster the development of NFT real estate and attract more global investors to invest in Vietnam proptech empowered by blockchain technology. Real estate investment promises a very high ROI with the least risk among other investment types (e.g stocks, crypto, saving, open-ended funds, etc.); however, its characteristic creates high entry barriers for individual investors, including big investment capital and an inconvenient, time intensive multiple-transaction process. METAIN is the blockchain-empowered co-investment platform focusing in real estate, whose vision is to provide high-yield, transparent and secured investment opportunities to middle-income customers. The platform aims to grow the Vietnam real estate investment market and improve its accessibility using blockchain technology to complement, not replace, existing reliable approaches. To guarantee its commitment of protecting individual investors, METAIN is following REIT regulation, partnering with high reputation firms for bank trustee service, tax and financial auditing and legal consulting. Those globally recognized partners would be announced shortly within the next month. IDG Capital also shows their ambition to lead the NFT Real estate trend and reveal their plan to proactively engage with global investors to attract investment into the Vietnam real estate market. About the potential of METAIN, Mr. Duc Tran – General Partner at IDG Capital Vietnam said: “METAIN is the first blockchain startup that IDG Capital Vietnam invests in. Unlike other similar projects, METAIN team has a very smart approach in their choice of investment targets. Income-producing property is real estate you invest in to make money from current rental payments, appreciation in market price, or adding value with additional revenue streams. Last but not least, their aims are only around Central Business District properties whose evaluations are the most stable with an all-time uptrend, comparing to other options.”  “With the high security, instantaneous settlement, transparent seamless transaction process blockchain, smart contract and NFT (Non-fungible token) technology is transforming the real estate industry and will become the key trend in the next decades. The next challenges would be how to protect investors’ pennies with a reliable setup and how to grow these pennies via choosing right investment assets to acquire. And we believe that we are on the right track of that.” said Mr. Nhan Tran, CEO of METAIN. Social Links: Twitter: https://twitter.com/METAINio Facebook: https://www.facebook.com/MetainOfficial Telegram: https://t.me/metainglobal Discord: https://discord.io/METAINio  IDG Website: https://www.idgcapitalvietnam.com/ Media Contact Company Name: METAIN INVESTMENT GROUP INC. Contact Person: Ms. Denise Thi, CMO  Company E-mail: denise.thi@metain.io Website: https://metain.io SOURCE:  METAIN INVESTMENT GROUP INC. The article is provided by a third-party content provider. SEAPRWIRE makes no warranties or representations in connection therewith. Any questions, please contact cs@SEAPRWIRE.com Sectors: Top Story, Daily News SEAPRWIRE (www.seaprwire.com) offers newswire service in Southeast Asia (Indonesia, Thailand, Vietnam, Singapore, Malaysia, Philippines & Hong Kong )

Read More
Posted on

The Ongoing Quest for Advancing Indonesia’s State-Owned Enterprises (SOEs)

JAKARTA, Feb 24, 2022 – (ACN Newswire) – President Joko Widodo harbors many hopes and expectations for Indonesia’s State-Owned Enterprises (SOEs), and strives to see them succeed not only at a national level, but also at an international level. The President believes these SOEs hold vast potential to dominate the essential sectors earlyon, and move to the global level as they mature. SOEs Minister Erick Thohir (ANTARA/HO-KBUMN) Yet SOEs require professional management and a helping hand to assist them on their way. However great, any company that falls into the hands of mis-management will experience under development and and ultimate demise. To survive this fourth industrial revolution, companies need to elevate human resources and ecosystems to the highest standards. In theory, transformation coupled with technological adaptation will follow. Indonesian SOEs Minister Erick Thohir spoke of three big dreams for SOEs, the first being larger SOE contributions to the nation. “If it is not my wishful thinking, it is how to enable SOEs to make a bigger contribution to the country. That is number one,” Thohir wrote on his official Instagram account @erickthohir on Feb 20. The second dream involves the number of State-Owned Enterprises becoming less, but therefore larger in terms of the average footprint. The third dream pertains to rationalizing and optimizing the role of SOE services in the community. Each of these three dreams have Key Performance Indicators or KPIs. SOEs have been undergoing a massive and ongoing transformation. It has borne fruit; for the first half of 2021, SOEs reported an income of Rp96 trillion, and net profit of Rp26 trillion. Reflecting on an improved state of affairs, Erick suggested that the restructuring program among State-Owned Enterprises had been going well. It turns out that SOEs behaved more efficiently as they realized greater profits, bringing the total number of SOEs from 108 to 41, and SOE sectors from 27 to 12, comprised of mineral and coal, forestry and plantations, foods, healthcare, finance and insurance, telecommunication, infrastructure and logistics, and several others. Thohir’s ministry was successful in reducing the niumbers of SOE companies, and SOE sectors, which he had deemed too great, focusing instead on specific SOEs or segments to incorporate his tranformative notions. Among the groups undergoing transformation, the State-Owned Banks showed some tangible results. The minister noted that the State-Owned Bank Association (Himbara) profit rose by 78% in 2021, while the banks remained focused on their respective segments: BRI (Indonesian Peoples Bank) catering to MSMEs, company-oriented Mandiri Bank, BNI (Indonesian State Bank) with its international scope, and BTN (State Savings Bank) of housing-related financial services. The Himbara Association gained around Rp72.05 trillion in profit in 2021, much improved from their combined profit of Rp40.34 trillion in 2020. BRI contributed Rp 30.76 trillion to this total, Mandiri Rp28.03 trillion, BNI Rp10.89 trillion, with BTN pitchig in for Rp2.37 trillion. Syahrul Ramadhan, Coordinator of Millennial Indonesia’s MSME and Business Sector, lauded Erick’s initiatives, encouraging the banks to such lofty achievements. Under Thohir’s command, for example, less-experienced directors had been replaced with seasoned professionals, the means to generate more profits for the state. Moreover, a business sector mapping was undertaken since the SOEs had so many businesses; some SOEs weren’t even sure what their focus sector was. Deputy Head of Commission VI, House of Representatives, Martin Manurung seconded a motion recognizing the adjustments of State-Owned Enterprises as ongoing. Although there are issues here and there, overall, it is doing well. Indeed troubles from the past still linger, though the Commission VI and the government are both committed to the betterment of the situation, as was apparent from their meetings. Manurung affirmed that President Joko Widodo (Jokowi) hopes that a future will materialize through Revisions of the SOEs Laws, which are currently being prepared by his administration. Manurung concluded by commending Jokowi’s promotion of government investment. Government Capital: the rules Essentially, the commission and the ministry are on the same boat for most aspects in the quest to improve SOEs. These include restructuring, holdings, clusters, and investments, among others. The commission also agrees to some suggestions made by SOEs that received Government Capital for company acts. In some instances, the discussions of Government Capital cannot be avoided. It should be ensured that capital is used for boosting the SOEs productivity, thereby offering significant contributions to the state in the form of dividend, tax, and more. President Jokowi drew attention to several SOEs that had received excess government capital as a means of protecting continuation, despite making no meaningful contribution to the state, and it has often been stressed that capital should not be used as a way to cover losses caused by faulty management, he insisted. The president gave stern warning that no such cases should recur. In fact, he also suggested that the dying companies be closed right away in lieu of having government capital being handed over to them. The president has sought for such action not out of malice or cynicism but rather based on the spirit to see the companies achieve success together, an expectation which hopefully does not end in dreams. (c) ANTARA 2022. Reporters: Hanni Sofia, Mecca Yumna; Editor: Rahmad NasutionANTARA/HO-KBUMN: http://newsechoasia.com/wp-content/uploads/2022/02/874a7765-low_antara202202242.jpg

Read More
Posted on

Aditya Birla Sun Life AMC Limited’s offshore arm appoints Sarath Sathkumara to head investments for its international business

DUBAI, Feb 9, 2022 - (ACN Newswire via SEAPRWire.com) - Aditya Birla Sun Life AMC Limited's (ABSLAMC) offshore subsidiary has appointed Mr. Sarath Sathkumara to lead investments for its international business.Aditya Birla Sun Life AMC Limited is the fourth largest asset manager in India with total assets under management of close to $42 billion. The publicly listed company has its presence in over 280 locations pan-India and present in international markets such as Dubai, Singapore, and Mauritius. It also operates via UCIT to cater to European markets. The company recently received approval from International Financial Services Centres Authority (IFSCA) to carry out Portfolio Management Services from GIFT City in India that will help to expand its reach and service to global clients. Aditya Birla Sun Life AMC Limited's offshore subsidiaries manage money to the extent of USD 1.32 billion. ABSLAMC is a subsidiary of Aditya Birla Capital Limited (a non-bank financial services conglomerate), and investment manager to Aditya Birla Sun Life Mutual Fund (ABSLMF).Commenting on his appointment, Mr. A. Balasubramanian, MD & CEO, Aditya Birla Sun Life AMC Limited said, "We are delighted to have Sarath Sathkumara come on board. He is a seasoned global emerging markets investor with over 30 years of experience in international capital markets and investing. His rich experience, illustrious background and in-depth knowledge of global markets will be an instrument in capitalizing overseas opportunities and launching investment solutions that cater to the needs of international investors. This further strengthens our overseas presence and aligns with our strategy of expanding our offshore business. Sarath will initially focus on launching ESG centered products, along with relevant solutions to cater to GIFT City and overseas clients".In his current role with ABSLAMC's offshore arm, Sarath has joined as CIO International. Most recently, Sarath was the Managing Director/Portfolio Manager for Taiyo Pacific Partner's India engagement investing business, starting the business 10 years ago and building it ground up. Prior to that, he has worked as a Chief Investment Officer of SBI Venture Capital in Singapore. From 2002 to 2008, Sarath was a Senior Portfolio Manager with the State Street Global Advisors' Active Emerging Markets Group (AUM $12bn), focusing on Asia and MENA regions. Before that Sarath spent 7 years with Capital International in Singapore as part of Capital International's Emerging Markets team (AUM $24bn). He was instrumental in building and running Capital's India business from 1993, the year India opened for foreign investment and witnessed India's capital market transformation. Before that he was with HSBC Group for 10 years in investment and corporate banking in Dubai, San Francisco and New York.About Aditya Birla Sun Life AMC LimitedEstablished in 1994, Aditya Birla Sun Life AMC Limited (ABSLAMC) is a joint venture between the Aditya Birla Capital Limited and Sun Life (India) AMC Investments Inc. ABSLAMC is primarily the investment manager of Aditya Birla Sun Life Mutual Fund, a registered trust under the Indian Trusts Act, 1882. ABSLAMC also operates multiple alternate strategies including Portfolio Management Services, Real Estate Investments and Alternative Investment Funds. ABSLAMC is one of the leading asset managers in India, with a pan India presence across 280 plus locations and a total AUM of over Rs. 3,109 billion under its suite of mutual fund (excluding our domestic FoFs), portfolio management services, offshore and real estate offerings and 7.6 million investor folios for the quarter ending December 31, 2021.For any media queries, please contact: Amrita Panja Email: Amrita.Panja@adityabirlacapital.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

创新奇智香港招股进行中 奋力冲刺“AI+制造”第一股

HONG KONG, Jan 21, 2022 - (亚太商讯 via SEAPRWire.com) - 青岛创新奇智科技集团股份有限公司（以下简称“创新奇智”）于昨日在香港正式启动招股，这标志著中国快速发展的企业AI解决方案提供商——创新奇智离IPO只差临门一脚，即将叩开港股市场的大门。据悉，创新奇智自成立以来，致力于利用前沿的AI技术提供AI相关产品及定制的商业解决方案，使客户能够提高运营效率及商业价值，并实现数字化转型，在中国企业AI解决方案行业取得了令人瞩目的成绩。根据弗若斯特沙利文的资料，于2020年，以收入计，创新奇智为中国企业级AI解决方案市场上第三大AI技术驱动型解决方案供应商、中国制造业AI解决方案市场最大的AI技术驱动型解决方案供应商。AI大咖李开复任董事长 软银加注基石高度看好创新奇智拥有一个富有企业服务经验及行业洞见的管理团队，董事长为在人工智慧界赫赫有名的李开复博士，其在美国哥伦比亚大学取得计算机科学学士学位，并以最高荣誉获得卡耐基梅隆大学博士学位。李开复博士曾任谷歌中国全球副总裁兼大中华区总裁及微软、SGI及苹果的高管，于2009年创立Sinovation Ventures Group（创新工厂），开辟中国风险投资和创业的一个新模式。此外，李开复博士还是世界经济论坛第四次工业革命中心的人工智能委员会联席主席，并于2013年被《时代》杂志评选为年度全球100位最具影响力人物之一。得益于强大的研发能力与优秀的管理团队，此次IPO，创新奇智共引入两名基石重磅投资者：SVF II ZEAL及Laurion Capital Master Fund，两名基石投资者同意认购至多2.04亿港元股份。其中，软银集团旗下的SVF II Zeal认购8379万~8698万港元股份，Laurion Capital Master Fund认购1500万美元股份。以软银为首的高质量基石投资者的认购，显示专业投资机构对于创新奇智发展前景的强烈看好，也极大增强了投资者对于公司未来上市表现的信心。深耕“AI+制造”领域 研发实力强劲产品组合丰富作为AI技术领域的先行者，创新奇智拥有丰富的AI产品及解决方案组合，能够满足不同用户需求。该公司的ABS（资产解决方案）或RDP（快速部署产品）可根据客户要求应用于各种业务场景，或根据客户要求透过整合多个ABS、RDP模块进行适当定制，进而为客户开发出一整套产品及解决方案。创新奇智的AI产品及解决方案可分为四个价值主题，即制造智能、边缘视觉、智能数据中心及智能数据治理。同时，亦为制造业提供整套AI产品及解决方案，即创新奇智智能制造系统(AIMS)，旨在以精准高效的方式满足多样化的客户需求。中国从制造大国正在坚定的迈向制造强国，人工智能在制造业企业的数字化转型中将发挥重要的作用。受惠于中国内地的新基建、《十四五智能制造发展规划》、专精特新等国家级产业政策红利，以及中国经济结构和劳动力结果的变化，中国制造业人工智能解决方案市场将迎来爆发式成长。据弗若斯特沙利文数据，预计到2025年，中国制造业的人工智能解决方案市场预计将达到约人民币649亿元。AI+制造方面，创新奇智的AI产品及解决方案主要帮助客户优化业务或生产流程，降低成本，提高营运效率、生产灵活性及实现业务运营及信息管理的智能化转型；AI+金融服务方面， AI产品及解决方案应用于智能数据中心智能基础设施及运营、智能混合云管理及智能数据治理及应用，旨在帮助金融机构提升IT基础设施可靠性，进而加强市场竞争力；AI+其他行业方面，主要为该等行业的客户提供AI产品及解决方案以使彼等业务运营的若干方面自动化及优化信息管理。此外，基于在深度学习领域的研究能力，创新奇智自主研发了专有AI平台，即ManuVision机器视觉智能平台、MatrixVision边缘视频智能平台和Orion分布式机器学习平台，强大的研发能力可以保证创新奇智运营及效率的根基，以及产品创新和服务能力。业绩增长强劲 客户群庞大且多样化雄厚的技术实力、多元化的服务组合及卓越的品牌优势，为创新奇智的业绩增长提供了有力保障。根据最新招股书，于2018年至2020年，该公司的收入分别为人民币0.37亿元、2.29亿元及4.62亿元，2018年至2020年的复合年增长率达252.5%；同期毛利润分别为人民币2339万元、7161万元及1.35亿元，2018年至2020年的复合年增长率为139.8%。2021年前三季度，实现营收5.53亿，同比增长85.8%，盈利前景长期看好。与此同时，创新奇智于制造、金融服务及其他行业积累庞大而且多样化的客户群。招股书数据显示，该公司已经累计为400多家客户提供基于AI的产品及解决方案，客户总数目由2018年的50名增至2020年的157名，并自截至2020年9月30日止九个月的111名增加至2021年同期的130名。优质客户的数目自2019年的13名增加至2020年的23名，优质客户的收入贡献百分比自2019年的49.8%上升至2020年的82.5%，优质客户以金额计算的复购率为112.7%。翻倍高增的业绩，庞大而且多样化的客户群，为公司构筑起宽广的护城河壁垒。获世界学术界及AI行业高度认可 未来成长空间可期随着研发实力的逐步增厚及盈利能力的显著增长，创新奇智受到了世界学术界及AI行业的高度认可。截至最后实际可行日期，该公司已申请634项AI相关专利，成功注册了126项AI相关专利，其中发明专利79项。自2018年初以来，该公司已在5个知名国际计算机视觉竞赛中揽获冠军，多篇学术论文入选IEEE举办的CVPR、ECCV及IEEE出版的期刊等世界知名行业会议和期刊。另据IDC发布的2021上半年人工智能市场份额报告，创新奇智在中国计算机视觉应用市场增速明显，跻身前5；机器学习平台市场份额位居第4的位置。公司还被研究机构Gartner列为全球机器视觉“Example Vendor”和人工智能计算机视觉“Cool Vendor”。纵观全球人工智能、IT行业，中国的企业级AI解决方案市场预期仍有巨大的增长潜力。根据弗若斯特沙利文的资料，2020年中国企业级AI解决方案市场的市场规模约达人民币1,394亿元，预计到2025年将达到约人民币8,366亿元，复合年增长率为43.1%。2020年，中国企业级AI市场约占整个AI市场的75.0%，预计到2025年将增至约80.0%，行业前景十分广阔。创新奇智作为中国企业级AI解决方案行业的新锐力量，此次启动香港IPO，标志著公司进入一个全新的发展阶段。未来，凭藉全面的产品组合、卓越的研发能力及优异的业绩，创新奇智将持续受惠于行业的高景气度，可以预见，于港交所上市后，在资本市场的加持之下，有望“会挽雕弓如满月”，实现新一轮腾飞。 Copyright 2022 亚太商讯. All rights reserved. (via SEAPRWire)

Read More
Posted on

Ingerson Capital Partners Releases the Performance Report on ‘Asia Driving Demand for Longer Trading Hours’

LONDON, Jan 21, 2022 - (ACN Newswire via SEAPRWire.com) - Ingerson Capital Partners today released a performance report on 'Asia Driving Demand for Longer Trading Hours'. The report has outlined that there is a significant rising desire for brokers and other investment professionals, including its own, to trade on markets based outside of their time zones during their local trading hours - with Asia demonstrating the leading the pack.Firms currently trading in extended sessions on international exchanges are driving the trend, with many of these financial institutions expressing some or significant interest in trading during extended hours trading sessions, according to researchers at Ingerson Capital Partners.Overall, Asia has the strongest demand, with a large percentage of financial institutions throughout the continent already trading extended hours, and firms that do not currently are showing a keen interest to look into it. The highest demand for extended hours comes from asset managers and hedge funds, representing the increasingly global reach of this market segment."As we continue to push the evolution of our markets and satisfy the increasing global appetite for European derivatives, launching extended hours in Asia was the next phase of our company's globalization strategy," explained Matthew Price who heads up the Capital Markets division for Ingerson Capital Partners."As we move forward, extended trading hours will better align our business with our global peers, boosting our international visibility and connecting us to more of our clients," he added.For firms currently trading extended hours, key drivers for the demand include capturing unique opportunities, requirements for trading strategies, the ability to respond to events throughout the day, and hedging considerations."The world is becoming a lot smaller in terms of investment firms' and their ability to trade globally, and the introduction of extended trading hours is a crucial move to facilitate that trend," said Simon Philips, Ingerson Capital Partners' Senior Vice President."The motivation from firms based in Asia, like our own, is to expand the scope of their trading activities and reflects the growing sophistication and vision of firms across this continent."For those firms that are not yet trading extended hours, the most vital importance is to capture unique opportunities relating to extended trading hours.About Ingerson Capital PartnersAt Ingerson Capital Partners, we provide a more personalized approach to managing your finances. We take the time to get to know you, learn about your goals, understand your lifestyle, and listen to your ambitions to create unique solutions for every financial stage of your life. Find out more by visiting: https://www.icpmanagement.com/Media ContactIngerson Capital Partners, Research Department.James Peterson, Head of Analytics.Broadgate Tower, 201 Bishopsgate, London, England, United Kingdom. EC2M 3ABinfo@icpmanagement.com+44 (0) 208 157 6450SOURCE: Ingerson Capital Partners Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More
Posted on

Verofax secures $1.5M in pre-Series A to expand its Traceability as a Service Offering

ABU DHABI, UAE, Jan 3, 2022 - (ACN Newswire via SEAPRWire.com) - Verofax Limited, an Asset Digitization and Traceability solutions provider, today announced closing a $1.5M pre-Series A round by international investors led by Benson Oak Ventures, with 500 Startups, Wami Capital and Vernalis Capital completing the group.Verofax utilizes patented technology incorporating Blockchain, Augmented Reality and Artificial Intelligence to provide 'Traceability as a Service', enabling brands to turn their offline products interactive, and manage their entire supply chain to trace goods, fend off counterfeit activities, and improve manufacturers' productivity. Brands can extend their reach directly to end-consumers, thereby increasing consumer intimacy with direct engagement, and leveraging the boom in NFTs and metaverse experiences.The funds will be used to expand the Company's sales and marketing activities on a global level, ahead of a planned Series A round later in 2022. Verofax solutions are applicable to a wide range of industries (Retail and CPG) and are already used by leading brands such as Anheuser Busch Inc. Verofax is a Microsoft Gold partner, and has secured a global network of distributors and resellers, and co-selling on enterprise solution platforms including Microsoft Appsource, Amazon AWS and Ant Group Antchain.Wassim Merheby, CEO of Verofax, said: "Our solution helps brands turn their products into a direct-to-consumer communication channel and deliver amazing experiences to drive growth and boost loyalty while also promoting greener product choices and ESG auditability. Verofax also helps turn give-aways into collectible and tradeable NFTs, interoperable across several metaverse environments. We are thrilled to be joined by investors that will help accelerate our growth trajectory through their collective expertise, network, and leadership."Robert Cohen, Managing Director of lead investor Benson Oak Ventures, said: "We have a very specific investment thesis that brands will leverage Web 3 & NFTs to reinvent their engagement & business models with consumers, creating entirely new service categories. Verofax has demonstrated early product market fit, leveraging its proprietary technology to sell its Traceability solution to many different types of brands and help them navigate this new world. We have been incredibly impressed by Wassim and the whole Verofax team, and thrilled to be making this our first investment in the UAE."Chetan Mehta, CEO of Wami Capital, said, "Verofax Blockchain-based traceability and validation solution empowers brands in the consumer goods and retail industry to promote sustainable products and allows consumers to choose greener brands and enjoy immersive experiences. Verofax traceability prevents counterfeiting in the supply chain across pharmaceutical, manufacturing, consumer, retail and logistics. We look forward to working with Verofax team to accelerate the adoption of their solution across our ecosystem."About VerofaxVerofax is a blockchain-enabled Asset Digitization and Traceability solution provider with a presence across North America, Europe, Asia and MEA regions. Verofax's solution is available across multiple cloud environments, helping businesses transform its physical products to interactive, and enable meaningful engagements with immersive user interfaces. For technical matters, visit Verofax at https://www.verofax.com or contact info@verofax.com.About Benson Oak VenturesBenson Oak, with a new office in Abu Dhabi, is a venture capital firm with 20 years experience in Europe, the US and the Middle East, with an increased focus on Web3 and 'passionware' - where everyone is a business. Investments have included Internet security leader AVG, video marketing platform Promo.com, crypto wallet ZenGo and HCM platform Harri. http://bensonoakventures.com.About Wami CapitalWami Capital, a single-family fund, focuses on supply chain activities of the Transworld Group. https://wamicapital.com.About 500 Startup Sanabil MENA Fund500 Startups (500), one of the most active global early stage venture capital firms, has partnered with Sanabil Investments, a financial investment company focused on global private investments in venture capital, growth and small buyout. This follows the recent announcement of the establishment of 500 Startups' new MENA regional headquarters in Riyadh. https://ecosystems.500.co/sanabil500accelerator.About Vernalis CapitalVernalis Capital is the family-owned investment company of Bala Chandra, founder of Vernalis. Vernalis Capital believes in providing entrepreneurs strategic leverage and seeks to build an ecosystem of synergistic companies which helps entrepreneurs pursue their own vision and goals while being supported wherever required. With a strong global network of partners and alliances, Vernalis Capital opens access to global managerial talent and mutually beneficial networking opportunities. https://www.vernaliscapital.com. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)

Read More